ArticleScientific reports2025
Use of antiviral medications during pregnancy and the likelihood of preeclampsia in a population-based register study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral infections and reactivations have been linked to several pregnancy complications. Antiviral medications are often prescribed as a prophylactic measure to prevent infant infection. This study examines associations between antiviral medication use during pregnancy and preeclampsia, thereby exploring links between viruses and such pregnancy complication. We analyzed data from 618,814 first-time mothers in Sweden (2007-2019) using four national registers. Of these 27,135 (4.4%) developed preeclampsia and 18,004 (2.9%) filled an antiviral medication prescription. Adjusted logistic regression with inverse probability of treatment weighting was used to evaluate associations between use of antiviral medication and preeclampsia. Antiviral medication use was associated with a reduced likelihood of preeclampsia (aOR 0.88; 95% CI, 0.81-0.96). Particularly, antiviral medication use was associated with a reduced likelihood of developing preeclampsia with delivery before 34 weeks gestation (aOR 0.66; 95% CI, 0.48-0.92) and preeclampsia with a small for gestational age infant (aOR, 0.74; 95% CI, 0.57-0.96). Timing of antiviral prescription filling was also investigated. Antiviral medication use in the third trimester was associated with a reduced likelihood of preeclampsia (aOR 0.77; 95% CI, 0.67-0.90), but not when used during the first two trimesters. Our study suggests that viral infections or reactivation might play a role in the etiology of preeclampsia, highlighting the need to further explore viral infections' role in preeclampsia development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.